A look at the biology behind one of the most closely watched experimental metabolic drugs in development, and an honest accounting of how far it still has to go before anyone can legally take it.
A Molecule With Three Jobs
Most drugs are built to do one thing well. Retatrutide was built to do three.
It is what pharmacologists call a triple hormone receptor agonist, a single injectable molecule engineered to activate three separate metabolic hormone receptors at once: GLP-1, GIP, and the glucagon receptor (GCGR). Each of those receptors already has an approved drug that targets it alone or in pairs. Semaglutide (Ozempic, Wegovy) activates GLP-1 by itself. Tirzepatide (Zepbound, Mounjaro) activates GLP-1 and GIP together. Retatrutide, developed by Eli Lilly, is the first molecule to reach late-stage human trials while engaging all three.
That third target the glucagon receptor is what separates retatrutide from the drugs that came before it, and it’s the reason a compound that has never been approved for anything has generated as much attention as it has. To understand why, it helps to start with what these receptors actually do inside the body, since the terminology (GLP-1, GIP, GCGR) shows up constantly in coverage of this drug class without much explanation of what any of it means.
The Hormones Behind the Headlines
GLP-1: the fullness signal
Glucagon-like peptide-1 is a hormone released by cells in the small intestine after a meal. It travels to the brain, the stomach, and the pancreas, where it does three things: it slows how quickly the stomach empties, it tells the brain that the body has had enough to eat, and it prompts the pancreas to release insulin only when blood sugar is elevated. That last property is what makes GLP-1 drugs useful for diabetes they nudge insulin release in a glucose-dependent way, which lowers the risk of the low blood sugar episodes that older diabetes drugs could cause.
Semaglutide was the drug that took this pathway from a diabetes therapy to a household name in weight management, largely because the appetite-suppression and slowed-digestion effects turned out to be powerful even in people without diabetes.
GIP: the confusing cousin
Glucose-dependent insulinotropic polypeptide is GLP-1’s biological relative another gut hormone released after eating, also involved in insulin release. For years, GIP had a strange reputation in metabolic research. Some early studies suggested that too much GIP signaling might worsen obesity, since GIP also plays a role in fat storage. Tirzepatide’s success in complicating that story: by activating GIP alongside GLP-1, it produced greater weight loss than GLP-1 drugs alone, suggesting the relationship between GIP and body weight is more complicated than researchers initially assumed. The leading theory now is that chronic GIP receptor activation, rather than acute stimulation, changes fat tissue behavior and improves insulin sensitivity in ways that complement GLP-1 rather than fighting it.
GCGR: the outlier
The glucagon receptor is the odd one out, because glucagon itself does the opposite of what dieters might want. Glucagon is the hormone that responds to low blood sugar by telling the liver to release stored glucose it is, in a sense, insulin’s counterpart. Activating the glucagon receptor on its own would be expected to raise blood sugar, not lower it, which is why GCGR looked like an unlikely target for an obesity drug when researchers first proposed it.
The reasoning that eventually justified it comes down to energy expenditure rather than blood sugar. Glucagon receptor activation increases the rate at which the liver burns fat and raises the body’s resting energy expenditure its passive calorie burn. In animal studies and early human trials, adding a dose of glucagon-receptor activity to a GLP-1/GIP backbone produced greater fat loss than the incretin hormones could achieve alone, apparently by burning more energy at rest rather than by farther suppressing appetite. The tradeoff is that glucagon receptor activation could theoretically push blood sugar upward, which is why retatrutide’s developers had to carefully balance the dose of each of the three components against each other leaning on GLP-1’s insulin-boosting effect to offset the sugar-raising tendency of glucagon signaling, while still capturing the calorie-burning benefit.
That balancing act is technically demanding. Glucagon, GLP-1, and GIP are all peptide hormones that bind to class B G-protein-coupled receptors (GPCRs), a receptor family known for being difficult to target with small-molecule drugs because their natural peptide hormones bind across an unusually long groove on the receptor surface, typically folding into an alpha helix to do so. Retatrutide, like its predecessors, is itself a modified peptide, engineered to fold into a shape that can activate all three receptors with different relative strengths a design challenge that helps explain why it took until the 2020s for a triple agonist to reach human trials, even though the underlying hormone biology has been understood for decades.
Why “Triple Agonist” Matters Clinically?
The pitch for combining three receptor targets in one molecule isn’t just theoretical tidiness. Each receptor contributes something the others don’t:
- GLP-1 suppresses appetite and slows gastric emptying the mechanism most responsible for eating less.
- GIP appears to improve fat-cell metabolism and insulin sensitivity, and may reduce the nausea that comes with GLP-1 activation alone, which is part of why tirzepatide is generally better tolerated at comparable doses than pure GLP-1 drugs.
- GCGR raises resting energy expenditure and increases fat oxidation in the liver, adding a calorie-burning effect on top of the calorie-suppressing effect of the other two.
The idea is that stacking these three mechanisms should produce weight loss that isn’t just about eating less, but about a body that is simultaneously less hungry, more insulin-sensitive, and burning more energy at rest three separate levers pulled by one weekly injection. Whether that idea holds up isn’t a matter of theory anymore. It’s now a matter of trial data, and Eli Lilly’s Phase 3 program has started producing exactly that.
The TRIUMPH Program
Eli Lilly’s registrational Phase 3 program for retatrutide is called TRIUMPH. It is a family of trials more than five thousand, eight hundred participants across the core studies each testing retatrutide in a different patient population or against a different comparator, plus a separate, much larger cardiovascular outcomes trial enrolling roughly ten thousand people that will report years later, on its own slower timeline. As of mid-2026, four of these readouts have reported results.
TRIUMPH-4: obesity with knee osteoarthritis
- This was the first Phase 3 trial in the program to report, in December 2025, and it studied adults with obesity or overweight who also had knee osteoarthritis a population chosen partly because excess weight is a major driver of joint stress and knee pain.
- Over 68 weeks, participants on the highest studied dose, 12 milligrams weekly, lost an average of 28.7% of their body weight, or roughly 71 pounds.
- The trial also tracked knee pain using a standard osteoarthritis pain scale (WOMAC) and found an average 75.8% reduction in pain scores, with more than one in eight retatrutide-treated participants reporting complete freedom from knee pain by the end of the study.
- Participants also saw improvements in cholesterol markers and blood pressure.
TRIUMPH-1: the pivotal general-obesity trial
- TRIUMPH-1, the largest and most closely watched trial in the program, reported topline results on May 21, 2026.
- It enrolled 2,339 adults with obesity or overweight who did not have type 2 diabetes, randomizing them to 4 mg, 9 mg, or 12 mg of weekly retatrutide, or placebo, over 80 weeks.
- At the top dose, participants lost an average of 28.3% of body weight about 70 pounds compared with 3.9% on placebo. The lower doses produced smaller but still substantial losses: 17.6% at 4 mg and 23.7% to 25.9% at 9 mg, depending on the analysis.
- Among a subgroup with a baseline BMI of 35 or higher who continued on an extension of the trial, average weight loss reached 30.3% at two years.
- Nearly half of participants on the 12 mg dose 45.3% lost 30% or more of their starting body weight, a threshold that historically has been associated primarily with bariatric surgery rather than medication.
- The trial also nested smaller sub-studies inside it: a sleep apnea analysis found a 60.6% average reduction in the apnea-hypopnea index, a standard measure of how often breathing is disrupted during sleep, among participants with moderate-to-severe obstructive sleep apnea at baseline.
TRANSCEND-T2D-1: a related diabetes-specific trial
- Reported at the American Diabetes Association’s 2026 Scientific Sessions, this trial part of a separate but related diabetes-focused program enrolled 537 adults with type 2 diabetes and found an average A1C (blood sugar) reduction of up to 2.0 percentage points from a baseline of 7.9%, with 90% of participants reaching an A1C below 7%, the American Diabetes Association’s general treatment target.
- Average weight loss in this population was 16.8% lower than in the non-diabetic TRIUMPH-1 population, which is a consistent pattern across the GLP-1 drug class; people with type 2 diabetes tend to lose somewhat less weight on incretin-based therapies than people without diabetes, likely reflecting underlying differences in metabolism.
TRIUMPH-2 and TRIUMPH-3: still pending
- Two more core trials remain outstanding as of this writing. TRIUMPH-2 mirrors TRIUMPH-1’s design but enrolls adults who have both obesity and type 2 diabetes together, rather than diabetes alone a distinction that matters because a positive result there could support a combined obesity-and-diabetes label, which has meaningful insurance-coverage implications, since diabetes treatment is more consistently covered by insurers than obesity treatment alone.
- TRIUMPH-3 studies a higher-risk population: adults with obesity and established cardiovascular disease, testing both efficacy and tolerability in people who are more likely to be on multiple other medications.
- Both are expected to report later in 2026, along with additional studies looking at retatrutide’s effect on metabolic-associated liver disease (MASLD, formerly called NAFLD or NASH) an area where earlier Phase 2 data showed unusually large reductions in liver fat and a separate maintenance-dosing study exploring whether a lower dose can sustain weight loss after an initial higher-dose induction period.
How Trials Like These Actually Work?
The numbers above carry weight because of how they were generated, and it’s worth pausing on the mechanics before treating any of them as settled fact.
Each TRIUMPH trial is randomized, double-blind, and placebo-controlled, meaning participants are assigned by chance to receive either retatrutide at a specific dose or an inactive placebo injection, and neither the participants nor the study staff administering treatment know who received which until the trial concludes.
This design exists specifically to prevent the placebo effect and researcher bias from inflating the apparent benefit of the drug which is why every result above is reported alongside its placebo comparison rather than in isolation. A 28% weight loss figure means little on its own; what matters is that the placebo group, given an inert injection and the same lifestyle counseling, lost only 3.9%, isolating the effect attributable to the drug itself.
Enrollment in these trials is also more restrictive than a typical prescription would be. Participants must meet specific body-mass-index thresholds, undergo baseline health screening, and agree to regular monitoring bloodwork, vital signs, and structured follow-up visits throughout the trial’s 68- to 80-week duration. That level of oversight is precisely what allows researchers to catch adverse events like the heart-rate changes or dysesthesia signal described below and characterize how common they are, rather than having them go unnoticed or unreported. It’s also what’s absent when a compound is obtained outside of a trial: the monitoring infrastructure is not a formality, it’s the mechanism by which side effects get detected and managed before they become serious.
Finally, it’s worth noting what these trials can’t yet tell us. Eighty weeks, the longest duration in the core program so far, is long by clinical-trial standards but still short relative to how long someone might realistically take a chronic weight-management drug potentially years or decades. Questions about what happens after five or ten years of continuous use, what happens to muscle mass over that timescale, and how weight and metabolic markers behave after a person eventually stops the drug are only partially answered by data collected so far, and some of them won’t have solid answers until the drug has been on the market, if it reaches the market, for a comparable length of time.
How It Compares to Semaglutide and Tirzepatide?
Journalists and researchers covering retatrutide inevitably compare it to the two drugs already on the market. On raw weight-loss numbers, retatrutide’s Phase 3 results are larger than what’s been published for either semaglutide or tirzepatide at comparable trial durations the roughly 28% average weight loss in TRIUMPH-1 exceeds the weight loss reported in tirzepatide’s own pivotal obesity trials, which centered closer to 21%. But bigger numbers come with a different side-effect profile, not simply a better one, and this is where the comparison gets more nuanced.
Gastrointestinal side effects nausea, vomiting, diarrhea, and constipation are common to all three drugs and are generally dose-dependent, meaning they show up more often and more intensely at higher doses and tend to ease once a person reaches a stable maintenance dose. In retatrutide’s Phase 3 data, nausea affected roughly 43% of participants at the 12 mg dose, compared to roughly 11% on placebo; vomiting affected around 21%; diarrhea around 33%; and constipation around 25%. Those rates are broadly similar to what’s been reported for high-dose semaglutide and tirzepatide.
What appears to be a genuinely new signal, not previously reported for semaglutide or tirzepatide, is dysesthesia a term for abnormal skin sensations such as tingling, burning, or heightened sensitivity to touch. In the TRIUMPH-4 trial, dysesthesia was reported in roughly 21% of participants at the 12 mg dose and around 9% at 9 mg, compared to under 1% on placebo. These events were generally described as mild and rarely led people to stop treatment, but researchers have flagged it as something worth continued monitoring as more data accumulates, since it isn’t yet fully understood mechanistically.
Retatrutide has also been associated with a dose-dependent rise in resting heart rate on the order of 5 to 10 beats per minute at higher doses a pattern seen to a lesser degree with tirzepatide as well. The increase tends to peak around week 24 of treatment and gradually decline afterward, and appears to reverse once treatment stops, though long-term data beyond the length of current trials doesn’t yet exist. Discontinuation due to side effects across the Phase 3 program has run somewhere between roughly 12% at 9 mg and 18% at the 12 mg dose, compared to around 4% on placebo figures that are in a similar range to what’s been reported for other high-dose incretin-based therapies, though not identical.
None of this means retatrutide is more dangerous than its predecessors; it means it is a different molecule with a different, still-incompletely-characterized profile, and the honest scientific position is that its full safety picture particularly anything related to long-term cardiovascular effects, pancreatic health, or what happens years after stopping the drug won’t be known until longer trials and post-approval monitoring have had time to accumulate data that simply doesn’t exist yet for any drug this new.
Where the Regulatory Process Actually Stands?
This is the part of the retatrutide story that gets flattened the most in casual coverage, so it’s worth stating plainly and completely.
Retatrutide is not approved for any use, anywhere, by any regulatory agency. It has no FDA approval, no prescribing information, no established dosing guidance for real-world patients, and no long-term safety data beyond what’s been collected inside its clinical trials. Everything described in this article the weight loss percentages, the side-effect rates, the trial names comes from a drug that currently exists only inside a controlled clinical trial program run by Eli Lilly, under the oversight of institutional review boards, trial physicians, and regulatory agencies that monitor the studies as they run.
Based on Lilly’s public statements and the pace of the TRIUMPH program, the company is expected to submit a New Drug Application to the FDA sometime around the fourth quarter of 2026 or the first quarter of 2027, once the remaining core Phase 3 trials have reported. A standard FDA review typically takes ten to twelve months from submission, which puts a realistic earliest approval date somewhere in late 2027, with broader patient availability more likely in early-to-mid 2028 and that timeline assumes no unexpected safety findings emerge in the meantime, no additional trials are required, and the FDA doesn’t request more information, any of which could push the timeline later. None of these dates are official; they are estimates built from the pace of a still-ongoing program, and Lilly itself has not confirmed a specific submission or approval date.
Until that process concludes, retatrutide is legally available only to people enrolled as participants in Lilly’s registered clinical trials, where dosing, monitoring, and safety oversight are built into the study design and supervised by trial investigators. It is not legally sold as a prescription medication, and it is not something a clinician can prescribe off-label the way some other drugs occasionally are, because it has not been approved for any indication at all off-label prescribing requires a drug to already have at least one FDA-approved use, which retatrutide does not have.
It’s also worth being direct about something that shows up frequently in online spaces discussing this drug: retatrutide is sometimes sold through websites describing it as a “research chemical” or “for laboratory research use only,” often alongside consumer-facing marketing, dosing suggestions, and discount codes. That combination is a significant red flag. Legitimate laboratory research use doesn’t typically come packaged with the kind of consumer marketing reviews, coupon codes, dosage discussion aimed at individual use found on sites selling these compounds to the public. An unapproved, unregulated compound obtained this way carries meaningfully different risks than the same compound administered inside a monitored clinical trial: there’s no verified purity or dosing accuracy, no medical supervision to catch adverse reactions early, and no guarantee that what’s in the vial matches what’s on the label. The clinical trial data summarized in this article reflects outcomes in a tightly controlled research setting it says nothing reliable about what happens when the same molecule, or something claiming to be the same molecule, is obtained and used outside of that setting.
Why the TRIUMPH Research Matters to Millions of People Around the World?
None of the regulatory caution above is a reason to dismiss what the TRIUMPH trials have actually shown. If the pending trials confirm what TRIUMPH-1 and TRIUMPH-4 have already reported, retatrutide would represent a genuine step change in what’s pharmacologically achievable for obesity and its downstream complications weight loss in the range historically associated with bariatric surgery, delivered through a once-weekly injection, alongside meaningful improvements in joint pain, sleep apnea severity, blood sugar control, and cardiovascular risk markers, all in the same patient population. That’s a legitimately significant scientific story, independent of any single company’s marketing.
It’s also a useful case study in how modern drug discovery works: not a single silver-bullet mechanism, but a careful engineering exercise in balancing three separate biological signals against each other, informed by decades of basic research into gut hormones that most people had never heard of a few years ago. The story of GLP-1, GIP, and GCGR and how researchers learned to combine all three in one molecule is, in its own way, as interesting as the weight-loss numbers that tend to dominate the headlines.
What the science does not yet support is any claim that retatrutide is ready for individual use outside of a clinical trial or, eventually, a legitimate prescription once and if it clears regulatory review. The distance between “promising Phase 3 data” and “safe, approved medication with known long-term risks” is exactly the distance the remaining trials, the FDA review process, and post-market monitoring are designed to cover. Until that process runs its course, the responsible framing of this drug is the same one Lilly itself and every reputable clinical source uses: investigational, not approved, and not intended for use outside of supervised clinical research.
That distinction matters more, not less, as public interest grows. Drugs that generate this much attention before approval tend to attract exactly the kind of unregulated gray-market activity described earlier, and the gap between a compound’s genuine scientific promise and its actual legal availability is where that activity thrives. Reading the TRIUMPH results accurately means holding both facts at once: the underlying science is a real and significant advance in metabolic pharmacology, and the drug itself is, for now, something that exists only inside a research program with years of review still ahead of it.
The Myths About Retatrutide and Potential Reasons: Disproportionate Lean Mass Loss During Pharmacological Weight Reduction
A significant and highly debated misconception surrounding modern metabolic peptides (such as GLP-1 and GIP/GLP-1 receptor agonists) is that they cause severe, indiscriminate muscle wasting. While it is a physiological reality that rapid weight loss inherently includes the loss of lean mass alongside fat, the controversy lies in the proportion and long-term metabolic consequences of this loss. Clinical data indicates that up to 20% to 40% of the total weight lost on these peptides can be lean tissue, including muscle and bone density. This has sparked the colloquial phenomenon of “Ozempic face” or “Ozempic butt,” referring to the rapid loss of subcutaneous fat and underlying muscle volume in specific areas. The broader medical concern is that in older adults or those already at risk for frailty, this accelerated sarcopenia could lead to decreased mobility, increased fall risk, and a lower resting metabolic rate, potentially setting the stage for rapid fat regain if the medication is discontinued.
Potential Reasons Behind the Controversy
The controversy stems from a clash between the urgent public health need to reduce severe obesity and the physiological realities of rapid caloric deficit. Critics argue that the medical community and pharmaceutical marketing have historically overemphasized total scale weight loss while underemphasizing body composition. Furthermore, the rapid pace of prescribing has outstripped the integration of mandatory concurrent interventions, such as high-protein diets and progressive resistance training which are necessary to mitigate lean mass loss, leaving many patients vulnerable to unintended sarcopenia.
The Chronicity Conundrum: Rebound Weight Gain and the Perception of Lifetime Dependency
A pervasive misconception among the public and some patients is that obesity is an acute condition that can be “cured” with a finite course of peptide therapy, much like an infection is cured with antibiotics. Consequently, the revelation that discontinuing these peptides almost universally leads to rapid rebound weight gain and the return of cardiometabolic risk factors is often met with frustration and a sense of treatment “failure.” The controversy here is deeply rooted in how society and the medical establishment define obesity. While endocrinologists and obesity medicine specialists classify it as a chronic, relapsing disease akin to hypertension or type 2 diabetes, requiring lifelong management, the general public often views it as a lifestyle failing that can be permanently fixed with a temporary pharmacological “reset.”
Potential Reasons Behind the Controversy
The friction arises from the psychological, financial, and systemic implications of lifelong pharmacotherapy. Patients face the daunting prospect of indefinite monthly medication costs, which are often not covered by insurance for weight management, leading to fears of permanent financial dependency. Additionally, there is an ongoing scientific debate regarding whether continuous use of incretin mimetics leads to receptor downregulation or tachyphylaxis (diminishing returns over time), which complicates the narrative that these drugs can be safely and effectively used as a lifelong, static treatment without future dose adjustments or drug holidays.
The Compounding Conundrum: Equivalence, Safety, and the Proliferation of Unregulated Peptide Alternatives
Due to massive global shortages of FDA-approved brand-name peptides like semaglutide and tirzepatide, there has been an explosive rise in the use of compounded versions of these drugs. A major misconception is that these compounded peptides are chemically, clinically, and safely identical to their FDA-approved counterparts. In reality, compounding pharmacies often use different salt forms of the active ingredient (e.g., semaglutide sodium or semaglutide acetate instead of the specific formulation used in the branded drug) and are not required by the FDA to prove bioequivalence or conduct the rigorous clinical trials required of brand-name manufacturers. This has led to a highly controversial gray market where patients receive effective but unverified treatments, sometimes resulting in adverse events, inconsistent dosing, or contamination.
Potential Reasons Behind the Controversy
The controversy is driven by a collision between patient desperation for access and regulatory loopholes. On one hand, compounding pharmacies fill a critical gap, providing life-saving metabolic treatment to patients who cannot afford or access brand-name drugs. On the other hand, regulatory bodies and endocrine societies warn that the lack of standardized oversight compromises patient safety. The debate centers on whether the FDA should crack down harder on compounding pharmacies to protect patients from unverified “research peptides” sold online, or if the systemic failure of the pharmaceutical supply chain and high drug pricing justifies the widespread use of these unregulated alternatives.
Beyond Nausea: The Underestimation of Severe Gastrointestinal and Systemic Adverse Effects
It is a common misconception that the gastrointestinal side effects of metabolic peptides, such as nausea, vomiting, and diarrhea, are merely mild, transient inconveniences that everyone easily outgrows. While mild nausea is common during dose escalation, the controversy arises from emerging clinical reports and post-marketing surveillance highlighting severe, sometimes irreversible adverse effects. These include severe gastroparesis (stomach paralysis), bowel obstructions, and rare but life-threatening conditions like acute pancreatitis, gallbladder disease, and aspiration during anesthesia. The public perception, often shaped by direct-to-consumer advertising and social media, frequently minimizes these risks, portraying the drugs as having a “miraculous” side-effect profile compared to older, harsher weight-loss stimulants.
Potential Reasons Behind the Controversy
The controversy is fueled by concerns over informed consent and the aggressive marketing of these therapies. Critics argue that the immense financial incentives for med-spas, telehealth platforms, and prescribers have led to the downplaying of severe risks to maximize prescription volumes. Furthermore, because these peptides delay gastric emptying, they pose hidden risks for patients undergoing surgery requiring anesthesia, leading to recent warnings from anesthesiology societies. The debate highlights a systemic failure in adequately educating patients about the profound physiological alterations these drugs cause, leading to a surge in emergency room visits for severe dehydration and GI complications.
The “Magic Bullet” Fallacy: Pharmacotherapy as a Substitute for Comprehensive Lifestyle Intervention
Perhaps the most dangerous misconception surrounding metabolic peptides is the “magic bullet” fallacy, the belief that the pharmacological suppression of appetite and delay of gastric emptying renders dietary quality, nutritional balance, and physical exercise obsolete. Patients often assume that because they are no longer hungry, they can consume highly processed, nutrient-poor foods without consequence, or that the drug alone will improve their cardiovascular health without lifestyle changes. However, clinical reality dictates that while peptides are unparalleled in reducing caloric intake, they do not inherently improve the nutritional quality of the diet. Without conscious effort, patients on these drugs can easily develop severe protein, vitamin, and mineral deficiencies, alongside a loss of cardiovascular conditioning due to reduced physical activity.
Potential Reasons Behind the Controversy
The controversy stems from the medicalization of obesity and the shifting paradigm of treatment protocols. Historically, obesity treatment required intensive behavioral therapy, nutritional counseling, and exercise prescriptions. The sheer efficacy of modern peptides has led many telehealth companies and prescribers to adopt a “pill-only” (or “injection-only”) approach, bypassing comprehensive lifestyle interventions to cut costs and scale operations rapidly. The debate among obesity specialists is whether the medical community is creating a generation of patients who are thinner but still metabolically unhealthy and malnourished, arguing that peptides must be viewed as an adjunct to, rather than a replacement for, foundational lifestyle medicine.
Top Doctors and Scientist Behind the Development of Retatrutride
1. Dr. Ania M. Jastreboff
Dr. Ania M. Jastreboff is a leading expert in obesity medicine and the Director of the Yale Obesity Research Center at the Yale School of Medicine. She served as the lead author and principal investigator for the landmark Phase 2 trial of retatrutide, the results of which were published in the New England Journal of Medicine in 2023. Her research focuses on the pathophysiology of obesity, bariatric surgery outcomes, and the clinical translation of incretin-based therapies. Dr. Jastreboff’s leadership was instrumental in designing the trial protocols, overseeing the patient cohorts, and demonstrating retatrutide’s unprecedented weight-loss efficacy, establishing her as a central figure in modern obesity pharmacotherapy.
2. Dr. Lee M. Kaplan
Dr. Lee M. Kaplan is the Director of the Obesity, Metabolism, and Nutrition Institute at Massachusetts General Hospital and a Professor of Medicine at Harvard Medical School. A globally recognized pioneer in the study of the gut-brain axis and the metabolic mechanisms of bariatric surgery, he served as a key co-author on the foundational retatrutide Phase 2 publications. Dr. Kaplan’s deep expertise in how gastrointestinal hormones regulate appetite and energy expenditure provided critical scientific context for the trial. His involvement helped bridge the gap between basic gastrointestinal neuroscience and the clinical application of triple-hormone agonists like retatrutide.
3. Dr. Juan P. Frías
Dr. Juan P. Frías is the President and Founder of Velocity Clinical Research (formerly the Metabolic Research Institute), one of the world’s largest and most prominent clinical research organizations dedicated to metabolic diseases. With hundreds of publications to his name, he has been a principal investigator in the clinical development of nearly every major incretin therapy over the last two decades, including tirzepatide and retatrutide. Dr. Frías’s extensive network of clinical sites and his deep understanding of trial execution were vital in rapidly and efficiently enrolling patients for the retatrutide Phase 2 and Phase 3 (TRIUMPH) programs, ensuring robust data collection on the drug’s safety and efficacy.
4. Dr. Julio Rosenstock
Dr. Julio Rosenstock is the Medical Director of the Dallas Diabetes Research Center and a Clinical Professor of Medicine at the University of Texas Southwestern Medical Center. With over 700 peer-reviewed publications and tens of thousands of citations, he is one of the most prolific and influential clinical investigators in the history of diabetes and obesity research. Dr. Rosenstock has been a key opinion leader and principal investigator for almost all major GLP-1 and GIP receptor agonists. His participation in the retatrutide trials brought decades of experience in evaluating the glycemic and weight-loss outcomes of novel peptides, helping to rigorously validate the drug’s clinical profile.
5. Dr. Tamer Coskun
Dr. Tamer Coskun is a research scientist at Eli Lilly and Company, where he played a foundational role in the discovery and early development of retatrutide. His expertise lies in peptide engineering and the molecular design of multi-receptor agonists. Dr. Coskun was directly involved in optimizing the structural balance of the retatrutide molecule to ensure it effectively activates the GIP, GLP-1, and glucagon receptors simultaneously without losing potency. His preclinical and translational research laid the biochemical groundwork that allowed retatrutide to progress from a molecular concept into a highly successful clinical candidate.
6. Dr. Axel Haupt
Dr. Axel Haupt is a Senior Medical Director and clinical pharmacologist at Eli Lilly and Company, specializing in metabolic diseases and clinical pharmacology. He has been deeply involved in the clinical development strategy for retatrutide, overseeing its pharmacokinetic and pharmacodynamic profiling. Dr. Haupt’s work ensures that the dosing regimens used in clinical trials are optimized for maximum efficacy while minimizing adverse effects. His expertise in translating preclinical pharmacological data into human clinical trial designs was crucial in establishing the safe and effective dose-escalation protocols used in the retatrutide Phase 2 and Phase 3 studies.
7. Dr. Mark L. Hartman
Dr. Mark L. Hartman is a senior clinical investigator and endocrinologist at Eli Lilly and Company. With a strong background in endocrine physiology and clinical trial management, he has overseen the clinical execution and endocrine safety monitoring for the retatrutide development program. Dr. Hartman’s role involves evaluating the drug’s impact on the broader endocrine system, ensuring that the profound weight loss and metabolic improvements do not come at the expense of hormonal imbalances. His leadership has been key in guiding the retatrutide program through the rigorous regulatory and clinical milestones required for advanced-phase trials.
8. Dr. Zvonko Milicevic
Dr. Zvonko Milicevic is a Medical Director at Eli Lilly and Company with extensive expertise in clinical trial operations, biostatistics, and metabolic disease research. He has played a critical role in the data analysis, efficacy endpoint evaluation, and safety reporting for the retatrutide trials. Dr. Milicevic’s work involves synthesizing complex clinical data from thousands of trial participants to accurately quantify the drug’s impact on body weight, HbA1c, liver fat, and cardiometabolic risk factors. His analytical rigor ensures that the clinical claims made for retatrutide are backed by robust, statistically sound evidence.
9. Dr. Adil Fatakia
Dr. Adil Fatakia is a Principal Investigator at Tandem Clinical Research, LLC, specializing in Phase 2 and Phase 3 metabolic and obesity trials. As part of the broader retatrutide clinical trial network, he was responsible for managing patient recruitment, overseeing the administration of the study drug, and ensuring strict adherence to the trial protocol at his site. Dr. Fatakia’s hands-on clinical management ensured high-quality data collection regarding patient tolerability, dose-escalation safety, and real-world clinical outcomes, contributing to the overall success of the multi-site Phase 2 study.
10. Dr. Evelyne Davidson
Dr. Evelyne Davidson is the Lead Investigator at New Phase Research and Development, with a specialized focus on obesity, endocrinology, and clinical pharmacology. During the retatrutide trials, she conducted on-the-ground clinical assessments, including the oversight of DEXA scans used to measure changes in body composition (fat mass vs. lean mass). Dr. Davidson’s meticulous attention to adverse event monitoring and patient safety protocols was vital in capturing the nuanced clinical data required to understand the physical and metabolic impacts of the triple agonist on trial participants.
11. Dr. Susan Brian
Dr. Susan Brian is an endocrinologist at the Cotton O’Neil Diabetes and Endocrinology Center, focusing on comprehensive diabetes and weight management. She contributed to the multi-site Retatrutide Phase 2 trial by managing patient cohorts and evaluating the drug’s effects on glycemic control and weight reduction in a community-based clinical setting. Dr. Brian’s expertise in managing complex metabolic disorders allowed her to effectively monitor patients with comorbidities, ensuring that the trial data reflected how retatrutide performs in a diverse, real-world patient population.
12. Dr. Stanley Hsia
Dr. Stanley Hsia is a veteran clinical investigator at Velocity Clinical Research, with extensive experience in cardiometabolic and obesity trials. He assisted in the rigorous screening, metabolic profiling, and longitudinal tracking of participants in the retatrutide studies. Dr. Hsia’s role involved closely monitoring patients’ cardiovascular and metabolic markers throughout the trial, providing critical data on how retatrutide influences not just body weight, but also blood pressure, lipid profiles, and overall cardiometabolic health.
13. Dr. Amina Haggag
Dr. Amina Haggag is the Medical Director at Anaheim Clinical Trials, LLC, with expertise in clinical pharmacology and obesity medicine. She oversaw the clinical site operations for the retatrutide trial, ensuring protocol adherence, proper dosing schedules, and patient safety. Dr. Haggag’s leadership at the site level was essential for maintaining the integrity of the clinical data, managing patient retention, and promptly addressing any adverse events, thereby ensuring the smooth execution of the trial’s demanding dosing phases.
14. Dr. Diana Widicus
Dr. Diana Widicus is an endocrinologist at the Springfield Diabetes & Endocrine Center, specializing in complex metabolic disorders and obesity pharmacotherapy. She played a key role in the community-level execution of the retatrutide trial, managing patient education, lifestyle counseling, and long-term follow-up. Dr. Widicus’s holistic approach to patient care ensured that participants received comprehensive support throughout the trial, which is critical for accurately assessing the long-term sustainability of weight loss and metabolic improvements achieved with retatrutide.
15. Dr. Sandro Bacchelli
Dr. Sandro Bacchelli is an investigator at Encore Medical Research, focusing on innovative treatments for metabolic syndrome, obesity, and related cardiovascular risks. He contributed to the Phase 2 trial by conducting detailed metabolic assessments and managing site-level regulatory compliance. Dr. Bacchelli’s work involved closely tracking the physiological changes in patients, providing valuable insights into the secondary endpoints of the trial, such as improvements in insulin sensitivity and reductions in hepatic steatosis (liver fat).
16. Dr. Cathy Barnes
Dr. Cathy Barnes is the Lead Physician at Suncoast Clinical Research, Inc., with extensive experience in Phase 2 and Phase 3 obesity trials. She managed her clinical site’s involvement in the retatrutide program, focusing on patient retention, accurate phenotyping of weight loss outcomes, and the management of gastrointestinal side effects, which are common with incretin therapies. Dr. Barnes’s clinical acumen helped optimize the patient experience during the trial, ensuring high compliance rates and reliable efficacy data.
17. Dr. Mae Sheikh-Ali
Dr. Mae Sheikh-Ali is the Medical Director at the East Coast Institute for Research, LLC, and an expert in lipidology, diabetes, and obesity. She brought specialized expertise in cardiometabolic risk reduction to the retatrutide trial, specifically evaluating the drug’s impact on lipid panels, inflammatory markers, and cardiovascular risk factors. Dr. Sheikh-Ali’s focus on the broader systemic benefits of retatrutide helped highlight the drug’s potential not just as a weight-loss medication, but as a comprehensive treatment for metabolic syndrome and cardiovascular risk.
18. Dr. Lisa Connery
Dr. Lisa Connery is an investigator at the Alliance for Multispecialty Research, LLC, focusing on multidisciplinary approaches to obesity and endocrinology. She coordinated the comprehensive care required for trial participants, ensuring that both metabolic and psychological aspects of obesity were monitored. Dr. Connery’s role was crucial in evaluating the holistic impact of retatrutide on patients’ quality of life, mental health, and overall well-being, providing a more complete picture of the drug’s clinical value.
19. Dr. Valerie Espinosa
Dr. Valerie Espinosa is an endocrinologist at Texas Diabetes & Endocrinology, P.A., specializing in diabetes management and advanced obesity pharmacotherapy. She actively managed patient cohorts in the retatrutide trials, with a specific focus on glycemic control, HbA1c reduction, and weight loss efficacy. Dr. Espinosa’s clinical insights were particularly valuable in understanding how retatrutide’s unique triple-agonist mechanism affects glucose homeostasis compared to single or dual agonists, contributing to the drug’s profile as a potential treatment for both obesity and type 2 diabetes.
20. Dr. Ronald Chochinov
Dr. Ronald Chochinov is the Director of the Coastal Metabolic Research Centre and a veteran endocrinologist and clinical researcher. He contributed to the retatrutide trial network by overseeing clinical site operations, patient safety protocols, and the collection of pivotal efficacy data. With decades of experience in endocrine clinical trials, Dr. Chochinov’s rigorous oversight ensured that the data generated from his site met the highest standards of scientific integrity, ultimately supporting the robust conclusions drawn from the retatrutide Phase 2 and Phase 3 programs.
This article is for informational and educational purposes only. It does not constitute medical advice. Retatrutide is an investigational compound that has not been approved by the FDA or any other regulatory agency for any use, and it should not be obtained or used outside of a supervised clinical trial. Anyone considering treatment for obesity, type 2 diabetes, or related conditions should consult a licensed healthcare provider about currently approved options.
